OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer.
Marcin Mikołaj GrzybowskiPaulina Seweryna StańczakPaulina PomperRoman BłaszczykBartłomiej BorekAnna GzikJulita NowickaKarol JędrzejczakJoanna BrzezińskaTomasz RejczakNazan Cemre Güner-ChalimoniukAgnieszka KikulskaMichał MląckiJolanta Pęczkowicz-SzyszkaJacek OlczakAdam GołębiowskiKarolina DzwonekPaweł DobrzańskiZbigniew ZasłonaPublished in: Cancers (2022)
OATD-02 is a potent small-molecule arginase inhibitor with optimal drug-like properties, including PK/PD profile. Excellent activity against intracellular ARG2 significantly distinguishes OATD-02 from other arginase inhibitors. OATD-02 represents a very promising drug candidate for the combined treatment of tumours, and is the only pharmacological tool that can effectively address the benefits of ARG1/ARG2 inhibition. OATD-02 will enter clinical trials in cancer patients in 2022.